NCT05134701 - Dapagliflozin Post Marketing Surveillance in HF and CKD | Biotech Hunter

Enrollment

815

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

May 20, 2024

Study Completion Date

May 20, 2024

Conditions

Heart FailureChronic Kidney Disease

Trial Locations (26)

2447

Research Site, Seoul

3080

Research Site, Seoul

4763

Research Site, Seoul

5355

Research Site, Seoul

6591

Research Site, Seoul

13590

Research Site, Seongnam-si

16247

Research Site, Suwon

34134

Research Site, Daejeon

35233

Research Site, Daejeon

41931

Research Site, Daegu

42415

Research Site, Daegu

47392

Research Site, Busan

48108

Research Site, Busan

49201

Research Site, Busan

51353

Research Site, Changwon

51472

Research Site, Changwon

54538

Research Site, Iksan

54907

Research Site, Jeonju

54987

Research Site, Jeonju

57931

Research Site, Suncheon

61469

Research Site, Gwangju

302-812

Research Site, Daejeon

02447

Research Site, Seoul

02841

Research Site, Seoul

158-710

Research Site, Seoul

480-130

Research Site, Uijeongbu-si